Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
OZEM
OZEM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
OZEM News
Last Week's Six Best-Performing ETF Sectors
Dec 17 2025
NASDAQ.COM
Top-Performing ETFs for November
Dec 02 2025
NASDAQ.COM
Novo Nordisk's Stock Decline Highlights the Side Effect of GLP-1 Investments: ETF Concentration Risk
Nov 24 2025
Benzinga
Eli Lilly Strengthens Position in $150B Obesity Drug Competition Amid Novo and Pfizer Rivalry — Potential Benefits for ETFs
Oct 30 2025
Benzinga
NVO Receives FDA Approval for MASH Therapy: ETFs Expected to Benefit
Aug 19 2025
NASDAQ.COM
ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data
Aug 08 2025
NASDAQ.COM
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Dec 13 2024
Benzinga
Tap the Weight-Loss Drug Market With These ETFs
Sep 18 2024
NASDAQ.COM
5 ETFs to Make the Most of Eli Lilly's Strength
Aug 12 2024
NASDAQ.COM
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Jul 18 2024
Benzinga
Best ETF Areas of Last Week
Jun 11 2024
NASDAQ.COM
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
Jun 07 2024
Benzinga
ETFs to Profit from the Weight Loss Drug Boom
Jun 04 2024
NASDAQ.COM
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
May 30 2024
Benzinga
This Week in ETFs: Roster of 17 New ETFs Includes 6 Buffer Funds
May 25 2024
NASDAQ.COM
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
May 23 2024
Benzinga
Show More News
